{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Debus JL"],"pubmed_abstract":["<h4>Background</h4>Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease in younger adults. Patients with MS (PwMS) are vulnerable to the presence of potential drug-drug interactions (pDDIs) and potential drug-food interactions (pDFIs) as they take numerous medications to treat MS, associated symptoms and comorbidities. Knowledge about pDDIs and pDFIs can increase treatment success and reduce side effects.<h4>Objective</h4>We aimed at determining the frequency and severity of pDDIs and pDFIs in PwMS, with regard to polypharmacy.<h4>Methods</h4>In the cross-sectional study, we analysed pDDIs and pDFIs of 627 PwMS aged ⩾18 years. Data collection was performed through patient record reviews, clinical examinations and structured patient interviews. pDDIs and pDFIs we"],"journal":["Therapeutic advances in chronic disease"],"pagination":["20406223221108391"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9358348"],"repository":["biostudies-literature"],"pubmed_title":["Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis."],"pmcid":["PMC9358348"],"pubmed_authors":["Zettl UK","Hecker M","Baldt J","Debus JL","Langhorst SE","Streckenbach B","Mashhadiakbar P","Bachmann P","Frahm N","Heidler F"],"additional_accession":[]},"is_claimable":false,"name":"Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.","description":"<h4>Background</h4>Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease in younger adults. Patients with MS (PwMS) are vulnerable to the presence of potential drug-drug interactions (pDDIs) and potential drug-food interactions (pDFIs) as they take numerous medications to treat MS, associated symptoms and comorbidities. Knowledge about pDDIs and pDFIs can increase treatment success and reduce side effects.<h4>Objective</h4>We aimed at determining the frequency and severity of pDDIs and pDFIs in PwMS, with regard to polypharmacy.<h4>Methods</h4>In the cross-sectional study, we analysed pDDIs and pDFIs of 627 PwMS aged ⩾18 years. Data collection was performed through patient record reviews, clinical examinations and structured patient interviews. pDDIs and pDFIs we","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T19:27:35.558Z","creation":"2025-02-19T01:57:06.17Z"},"accession":"S-EPMC9358348","cross_references":{"pubmed":["35959503"],"doi":["10.1177/20406223221108391"]}}